Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
BioAtla, Inc. (NASDAQ: BCAB)
BCAB Stock Predictions and Ratings
WSX Rating:
SELL
WSX Forecast (1yr):
-4.10%
Analyst Rating:
HOLD
Analyst Forecast (1yr):
NOT AVAILABLE
BCAB Stock Analysis
BCAB
PE Ratio:
BCAB
PEG Ratio:
Not Available
BCAB
Forward EPS Growth (12 month):
0.00%
BCAB
PS Ratio:
2.1
BCAB
PSG Ratio:
Not Available
BCAB
Forward Revenue Growth (12 month):
0.00%
BCAB Articles
No data was found